UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-07 | Future report Set alerts | |
| Q2 2022 | 2022-08-08 | -0.08 | -0.08 |
| Q1 2022 | 2022-05-09 | -0.52 | -0.52 |
| Q4 2021 | 2022-03-01 | -0.63 | -0.63 |
| Q3 2021 | 2021-11-08 | -0.02 | -0.02 |
| Q2 2021 | 2021-08-09 | -0.61 | -0.61 |
| Q1 2021 | 2021-05-10 | -0.47 | -0.47 |
| Q4 2020 | 2021-02-25 | 1.59 | 1.59 |
| Q3 2020 | 2020-11-09 | -0.35 | -0.35 |
| Q2 2020 | 2020-08-10 | -0.54 | -0.54 |
| 2016-05-06 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2016-05-06 | Reiterated Rating | Canaccord Genuity | Buy | $30.00 |
| 2016-04-23 | Reiterated Rating | Piper Jaffray | Overweight | $23.00 |
| 2016-04-23 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $23.00 |
| 2016-04-21 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2016-04-20 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-03-12 | Reiterated Rating | Janney Montgomery Scott | Buy | $23.00 to $18.00 |
| 2016-03-11 | Reiterated Rating | Cantor Fitzgerald | Buy | $28.00 |
| 2016-03-11 | Initiated Coverage | Needham & Company LLC | Buy | $27.00 |
| 2016-02-29 | Lower Price Target | Laidlaw | Buy | $30.00 to $17.00 |
| 2016-02-28 | Reiterated Rating | Cantor Fitzgerald | Buy | $28.00 |
| 2016-02-28 | Reiterated Rating | Needham & Company LLC | Buy | $27.00 |
| 2016-02-26 | Reiterated Rating | Piper Jaffray | Overweight | $23.00 |
| 2015-12-31 | Reiterated Rating | Piper Jaffray | Top Pick to Top Pick | $34.00 |
| 2015-12-11 | Initiated Coverage | Cantor Fitzgerald | Buy | $28.00 |
| 2015-12-09 | Reiterated Rating | Needham & Company LLC | Buy | $27.00 |
| 2015-12-09 | Reiterated Rating | Piper Jaffray | Buy | $34.00 |
| 2015-11-11 | Reiterated Rating | Needham & Company LLC | Buy | $27.00 |
| 2015-11-11 | Reiterated Rating | Canaccord Genuity | Buy | $30.00 |
| 2015-11-04 | Initiated Coverage | Janney Montgomery Scott | Buy | $28.00 |
| 2015-11-03 | Initiated Coverage | Cantor Fitzgerald | Buy | $28.00 |
| 2015-08-12 | Reiterated Rating | Canaccord Genuity | Buy | $30.00 |
| 2015-08-11 | Initiated Coverage | Needham & Company LLC | Buy | $27.00 |
| 2015-07-24 | Boost Price Target | Canaccord Genuity | Buy | $20.00 to $30.00 |
| 2015-07-24 | Reiterated Rating | Piper Jaffray | Buy | $30.00 to $34.00 |
| 2015-07-23 | Reiterated Rating | Needham & Company LLC | Buy | $22.00 to $27.00 |
| 2015-07-23 | Boost Price Target | Janney Montgomery Scott | Fair Value | $27.00 |
| 2015-06-24 | Set Price Target | Piper Jaffray | Buy | $30.00 |
| 2015-06-24 | Set Price Target | Needham & Company LLC | Buy | $22.00 |
| 2015-05-14 | Reiterated Rating | Canaccord Genuity | Buy | $20.00 |
| 2015-05-13 | Initiated Coverage | Needham & Company LLC | Buy | $22.00 |
| 2015-03-27 | Reiterated Rating | Canaccord Genuity | Buy | $20.00 |
| 2015-03-27 | Reiterated Rating | Needham & Company LLC | Buy | $22.00 |
| 2015-03-03 | Initiated Coverage | MLV & Co. | Buy | $26.00 |
| 2015-01-09 | Initiated Coverage | Canaccord Genuity | Buy | $20.00 |
| 2014-12-09 | Initiated | Summer Street Research | Buy | $20 |
| 2014-12-09 | Initiated Coverage | Summer Street | Buy | $20.00 |
| 2014-05-15 | Boost Price Target | Canaccord Genuity | $25.00 to $29.00 | |
| 2014-02-27 | Initiated | Needham | Buy | $27 |
| 2014-02-27 | Initiated Coverage | Needham & Company LLC | Buy | $27.00 |
| 2014-02-25 | Initiated Coverage | Canaccord Genuity | Buy to Buy | $25.00 |
| 2014-02-25 | Initiated Coverage | Stifel Nicolaus | Buy | $21.00 |
| 2014-02-25 | Initiated Coverage | Janney Montgomery Scott | Buy | |
| 2014-02-25 | Initiated Coverage | Piper Jaffray | Overweight | $23.00 |
| 2016-05-06 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2016-05-06 | Reiterated Rating | Canaccord Genuity | Buy | $30.00 |
| 2016-04-23 | Reiterated Rating | Piper Jaffray | Overweight | $23.00 |
| 2016-04-23 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $23.00 |
| 2016-04-21 | Reiterated Rating | Needham & Company LLC | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CARA 136 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 7.58M |
| Vanguard Group, Inc | 3.31M |
| Bain Capital Life Sciences Investors, LLC | 2.65M |
| FARALLON CAPITAL MANAGEMENT LLC | 2.50M |
| STATE STREET CORP | 1.88M |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1.70M |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.33M |
| DIMENSIONAL FUND ADVISORS LP | 1.01M |
| CHESAPEAKE PARTNERS MANAGEMENT CO INC/MD | 0.96M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.82M |
| BlackRock Institutional Trust Company, N.A. | 0.75M |
| NORTHERN TRUST CORP | 0.73M |
| PINNACLE ASSOCIATES LTD | 0.71M |
| BlackRock Fund Advisors | 0.69M |
| CAM Group Holding A/S | 0.58M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| RHO Ventures VI LP | 15.76% (3568057) | CARA / |
| VOGELBAUM MARTIN | 13.55% (3068057) | CARA / NRX / |
| Moller Charles Ph.D. | 6.96% (1576404) | CARA / |
| CHALMERS DEREK T President & CEO | 4.73% (1071392) | CARA / |
| Slagel Dean | 4.70% (1064338) | CARA / |
| Lewis Michael E Chief Scientific Advisor | 1.39% (314988) | CARA / |
| Menzaghi Frederique Ph.D. VP-Research & Development | 0.53% (119000) | CARA / |
| Schoell Josef Chief Financial Officer | 0.22% (50000) | CARA / |
| ALTA BIOPHARMA PARTNERS III LP | 0.19% (43212) | AEGR / CARA / CMRX / MGNX / SNSS / |
| Stauffer Joseph William Chief Medical Officer | 0.06% (13442) | CARA / DRRX / |
UM